摘要
目的:探讨分析小剂量茶碱缓释片和沙美特罗替卡松粉吸入剂联合治疗慢性阻塞性肺疾病的临床效果。方法:以我院2014年1月至2016年1月间,收治的50例COPD患者为研究对象,按照随机数字表方法分为观察组与对照组各25例,观察组患者予以0.1g茶碱缓释片,2次/天口服,+50/250μg沙美特罗替卡松粉吸入剂,2吸/天,联合治疗,对照组患者予以50/500μg沙美特罗替卡松粉吸入剂,2吸/天治疗,疗程均为6个月。结果:观察组患者肺功能指标与CAT评分皆明显优于对照组患者,总不良反应发生率(8.00%)明显低于对照组(32.00%),治疗费用平均为(2248.5±312.6)元明显低于对照组(2753.7±354.2)元,差异有统计学意义(P<0.05)。结论:小剂量茶碱缓释片和沙美特罗替卡松粉吸入剂联合治疗COPD,可以有效的改善肺功能、提高临床疗效、降低医疗费用,且安全性高,值得推广应用。
Objective： To investigate the clinical effect of small dose of Theophylline Sustained-release Tablets and Salmeterol Xi- nafoate and Fluticasone Propionate Powder for Inhalation combined treatment of chronic obstructive pulmonary disease. Methods： In our hospital from January 2014 to January 2016, 50 cases of COPD patients were selected as research objects, according to the random number table method divided into observation group and control group with 25 cases in each group, the patients in the observation group to Theophylline Sustained-release Tablets 0.1g, 2 times / day, oral ＋50/250 G Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation, 2 / day suction combined treatment, the control of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation g and 2 days of treatment to 50/500 / suction group, treatment of 6 months. Results： Patients with lung function index and CAT score were significantly better than the control group, the total incidence of adverse reactions （8%） was significantly lower than the control group （32%）, the average cost of treatment for （2248.5 ＋ 312.6） yuan was significantly lower than the control group （2753.7 ＋ 354.2）, the difference was statistically significant （P〈0.05）. Conclusion： A small dose of Theophylline Sustained-release Tablets and Salmeterol Xinafoate and Fluticasone P＇ropionate Powder for Inhalation combined with the treatment of COPD, can effectively im- prove lung function, improve clinical efficacy, reduce medical costs, and high safety, it is worthy of popularization and application.
作者
李德华
李敏
Li Dehua et al(Department of Internal Medicine, Zhongshan City Henglan Hospital （Guangdong Zhongshan 528478)
出处
《黑龙江医药》
CAS
2017年第3期499-502,共4页
Heilongjiang Medicine journal
基金
广东省医学科研基金资助项目(编号:B2012076)
关键词
茶碱缓释片
沙美特罗替卡松粉吸入剂
慢性阻塞性肺疾病
安全性
Theophylline Sustained-release Tablets
Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation
Chronic obstructive pulmonary disease
Safety.
